BerGenBio has signed a contract with Sygnature Discovery for the preclinical development of a small molecule inhibitor against a novel target that mediates highly aggressive drug-resistant tumors. Preclinical selection is anticipated in 2014. Financial terms were not disclosed. BerGenBio’s chief executive officer, Richard Godfrey, said, “In particular this previously ignored target has been shown to be an essential mediator in drug resistant melanoma and small cell lung cancer, and there is gro...